Novartis - Intimation Under Reg 30 Of SEBI LODR Regarding Entering Into Exclusive Promotion And Distribution Agreement With N 08/09/2026 09:53 Back Intimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising the products Accentrix (ranibizumab) and Pagenax (brolucizumab).